NCT02429466已完成1 期
Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Nasser Hanna
- 入组人数
- 14
- 试验地点
- 2
- 主要终点
- Maximum tolerated dose (MTD) of SGI-110 plus cisplatin
研究概览
简要总结
This is an open-label, single arm, Phase I dose escalation study in subjects with refractory germ cell tumor (rGCT). This phase I will evaluate the safety and efficacy of SGI-110 in combination with cisplatin in subjects with rGCT. The primary objective is to determine the maximum tolerated dose (MTD) of SGI-110 to be used prior to cisplatin. A total of 15 subjects will be enrolled in this study at the Indiana University Simon Cancer Center.
详细描述
Primary Objective:
To assess the safety and toxicity of guadecitabine (SGI-110) plus cisplatin including the dose limiting toxicity (DLT) and to determine the Maximum tolerated dose (MTD)
Secondary Objective:
To assess the efficacy of guadecitabine (SGI-110) to resume sensitivity to cisplatin in refractory GCT
Correlative Objective:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years old at the time of informed consent
- •Written informed consent and HIPAA authorization for release of personal health information.
- •Subjects who are willing and able to comply with the protocol and study procedures including willingness to undergo tumor biopsy for tumor cells before therapy at Cycle 1, Day 1, and Day 8 (before cisplatin dose) if this is clinically and safely feasible to do so.
- •Subjects with histologically or serologically confirmed diagnosis of recurrent germ cell tumor.
- •Subjects who have platinum-resistant disease. There is no limit on the number of prior treatment regimens.
- •Subjects must have had prior high dose chemotherapy (HDCT) treatment when indicated.
- •Subjects who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or elevated Tumor markers (hCG or AFP).
- •Note: patients without measurable disease are allowed on the study as long as they have clearly rising tumor markers and they will be exempt from biopsy.
- •Subjects with ECOG performance status of 0-
- •Subjects must be at least 3 weeks from last chemotherapy.
- •Females of childbearing potential must not be pregnant or breast-feeding. Male and female patients of reproductive potential must agree to use two forms of highly effective contraception from the screening visit through 30 days after the last dose of study drug. Acceptable forms of effective contraception include:
- •Oral, injected or implanted hormonal methods of contraception.
- •Placement of an intrauterine device (IUD) or intrauterine system (IUS).
- •Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
- •Male sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).
- •True abstinence: When this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.] Pregnancy tests for females of childbearing potential are required; must be serum at screening and the post treatment safety assessment visit. A positive urine pregnancy test must be confirmed by a serum pregnancy test and a pelvic US since some NSGCT may secrete beta-hCG and cause a false positive pregnancy. A pelvic US does not need to be repeated with each cycle unless the treating physician thinks it is necessary to do so.
- •The following laboratory values must be obtained within 14 days prior to registration for protocol therapy.
- •Absolute neutrophil count ≥ 1500 cells/mm3
- •Hemoglobin (Hgb) ≥ 8 g/dL
- •Platelets count ≥ 100,000 cells/mm3
- •Serum creatinine levels ≤ 1.5 mg/dl and calculated (by Cockcroft-Gault formula) or measured creatinine clearance ≥ 50 mL/min
- •Bilirubin ≤ 2 x ULN
- •Aspartate aminotransferase (AST, SGOT) ≤ 3 x ULN
- •Alanine aminotransferase (ALT, SGPT) ≤ 3 x ULN
排除标准
- •Active central nervous system (CNS) metastases. Subjects with neurological symptoms should undergo a head CT scan or brain MRI to exclude brain metastasis, at the discretion of the treating physician.
- •NOTE: A subject with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic.
- •Treatment with any investigational agent within 30 days prior to registration for protocol therapy.
- •Concurrent participation in a clinical trial which involves another investigational agent.
- •Subjects with Grade 2 or greater neuropathy.
- •Subjects with a life-threatening illness, medical condition or organ system dysfunction, or other reasons which, in the Investigator's opinion, could compromise the subject's safety, interfere with or compromise the integrity of the study outcomes including incomplete recovery from the acute effects from any prior anti-neoplastic therapy.
- •Pregnancy or breast-feeding.
研究组 & 干预措施
Guadecitabine (SGI-110)
Experimental
干预措施: Guadecitabine (SGI-110) (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD) of SGI-110 plus cisplatin
时间窗: During chemotherapy (weeks 1-18)
Dose limiting toxicity (DLT) of guadecitabine (SGI-110) plus cisplatin
时间窗: During chemotherapy (weeks 1-18)
次要结局
- Objective response rate (ORR)(Days 42, 84, 126, 159, and 220)
- Progression free survival (PFS)(Days 42, 84, 126, 159, and 220)
研究者
Nasser Hanna
Assistant Professor of Clinical Medicine
Indiana University School of Medicine
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative NeoplasmsMyeloproliferative NeoplasmsNCT03075826Weill Medical College of Cornell University22
已完成
1 期
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid TumorsOsteosarcomaWilms TumorDesmoplastic Small Round Cell TumorNeuroblastomaRhabdomyosarcomaEwing SarcomaNCT02982941MacroGenics25
招募中
1 期
A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C MutationAdvanced Solid TumorNCT06006793Shouyao Holdings (Beijing) Co. LTD50
尚未招募
1 期
A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusNCT06340490Guangdong Ruishun Biotech Co., Ltd24
终止
1 期
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLCNsclcNCT03990077Shanghai Kechow Pharma, Inc.2